ATRX and central nervous system cancer: Among gliomas with ATRX loss, 89% retained IDH1/2 mutations while ATRX retention in IDH1/2 mutants was strongly associated with 1p/19q loss, making this a differentiating feature associated with oligodendroglioma [266].